Hugo is about to joust da Vinci. It’s not a battle between Renaissance geniuses. Instead, a commercial fight is brewing ...

With the U.S. authorization for urologic procedures, “there is now choice” for hospitals that want to expand their robotic ...

Weispfenning has more than 25 years of experience at Medtronic, joining its IR team 17 years ago. He led the function at the ...

Medtronic issues recall diabetes software affecting CareLink version 4.2B due to incorrect glucose data display, prompting clinician review.

Ryan Weispfenning has elected to take up the challenge of creating and leading the investor relations function at the planned ...

Even if that will be an important step for Medtronic, Intuitive Surgical should remain the top player and still outpace its challenger. For one, it will take a long time for Medtronic's Hugo to earn ...

Medtronic's fair value estimate has nudged higher to $111.05 from $109.82 as analysts grow more confident that the company ...

Salmon retired from Medtronic in September after a more than 20-year tenure at the medtech giant. Most recently, Salmon ...

Medtronic plc is rated a Buy, expecting 10-11% annual total returns, supported by 7-8% EPS growth. Learn more about MDT stock ...

Though the Medtronic OmniaSecure is the world's smallest defibrillation lead, the product development story isn't one of ...

If you are wondering whether Medtronic is still a solid buy at around $101 a share, or if the easy money has already been ...

Hugo is heading to the U.S., with Medtronic finally securing a stateside clearance for its robotic surgery platform. | The ...